The present study will characterize the ability of pregnenolone to reverse the acute intoxication and associated symptoms of cannabis. Healthy adults with a history of cannabis use will be recruited to participate in a placebo-controlled, within-subject crossover study at Johns Hopkins Behavioral Pharmacology Research Unit (BPRU). By clarifying the ability of pregnenolone to reverse cannabis intoxication symptoms, this study will pave the way for larger clinical studies that provide a foundation for the development of future CB1-receptor NAM medications that could be applied in emergency situations and potentially validate pregnenolone as a treatment for cannabis intoxication.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Mean Peak Change From Baseline Drug Effect as Assessed by the Drug Effect Questionnaire (DEQ)
Timeframe: baseline and 1.5, 2, 3, 4, 5, 6, 7, and 8 hours post-dosing
Mean peak change from baseline psychomotor performance as assessed by the Digit Symbol Substitution Task (DSST)
Timeframe: baseline and 1.5, 2, 3, 4, 5, 6, 7, and 8 hours post-dosing
Mean peak change from baseline working memory performance as assessed by the Paced Auditory Serial Addition Task (PASAT)
Timeframe: baseline and 1.5, 2, 3, 4, 5, 6, 7, and 8 hours post-dosing
Mean Peak Levels of Blood Pregnenolone, THC, and THC metabolites (11-OH-THC, and THCCOOH. )
Timeframe: baseline and 1.5, 2, 3, 4, and 6 hours post-dosing
Mean Peak Change from Baseline Psychotomimetic effects as assessed by the Psychotomimetic States Inventory (PSI)
Timeframe: baseline and 1.5, 2, 3, 4, 5, 6, 7, and 8 hours post-dosing
Mean Peak Change From Baseline Heart Rate
Timeframe: baseline and 1.5, 2, 3, 4, 5, 6, 7, and 8 hours post-dosing
Mean Peak Change From Baseline Blood Pressure (mmHg)
Timeframe: baseline and 1.5, 2, 3, 4, 5, 6, 7, and 8 hours post-dosing